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ABSTRACT
Objectives: To examine cytomegalovirus (CMV)
seroprevalence and associated risk factors for CMV
seropositivity in pregnant Norwegian women.
Design: Cross-sectional study.
Setting: The Norwegian Mother and Child Cohort Study
(MoBa) in addition to two random samples of pregnant
women from Sør-Trøndelag County in Norway.
Participants: Study group 1 were 1000 pregnant
women, randomly selected among 46 127 pregnancies in
the MoBa (1999–2006) at 17/18 week of gestation. Non-
ethnic Norwegian women were excluded. Study groups 2
(n=1013 from 1995) and 3 (n=979 from 2009) were
pregnant women at 12 weeks of gestation from Sør-
Trøndelag County.
Outcome measures: CMV seropositivity in blood
samples from pregnant Norwegian women.
Results: CMV-IgG antibodies were detected in 59.9%
and CMV-IgM antibodies in 1.3% of pregnant Norwegian
women in study group 1. Women from North Norway
demonstrated a higher CMV-IgG seroprevalence (72.1%)
than women from South Norway (58.5%) (OR 1.83, 95%
CI 1.17 to 2.88). The CMV-IgG seroprevalence was
higher among women with low education (70.5%)
compared to women with higher education (OR 2.20,
95% CI 1.24 to 3.90). Between 1995 and 2009 the CMV-
IgG seroprevalence increased from 63.1% to 71.4% in
pregnant women from Sør-Trøndelag County (study
groups 2 and 3; p<0.001). The highest CMV-IgG
seroprevalence (79.0%) was observed among the
youngest pregnant women (<25 years) from Sør-
Trøndelag County in 2009 (study group 3).
Conclusions: The CMV-IgG seroprevalence of pregnant
Norwegian women varies with geographic location and
educational level. Additionally, the CMV-IgG
seroprevalence appears to have increased over the last
years, particularly among young pregnant women.
INTRODUCTION
Pregnancy is associated with a functional
immunosuppression and, thus, may increase
the risk of acquiring infections.1
Cytomegalovirus (CMV) infection is a
common viral infection in pregnancy2 and
may have severe consequences for the devel-
oping fetus.3 About 0.15–2.0% of live-born
neonates are infected with CMV4 and this
may result in symptoms ranging from sensori-
neural hearing loss to multiorgan failure.3
There is currently no effective treatment for
congenital CMV infection.5
The CMV virus persists in the host for life
and may become reactivated during preg-
nancy.6 Recurrent CMV infection may either
include reactivation of a latent virus or a
reinfection with a different CMV strain.6
About 1–4% of CMV-IgG seronegative preg-
nant women will acquire a CMV infection for
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The national population-based design and the
opportunity to assess regional differences in
cytomegalovirus (CMV)-IgG seroprevalence.
▪ The Norwegian Mother and Child Cohort Study may
be disposed to some self-selection. Such skewed
selection of women in the Norwegian Mother and
Child Cohort Study may potentially lead to an
underestimation of CMV-IgG seroprevalence.
▪ Two comparable study groups from the same
population with 14 years interval made it pos-
sible to give a good estimate of time trends in
CMV seroprevalence.
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the ﬁrst time during pregnancy7 8 and about 30% of these
transmit the virus to the fetus, resulting in congenital
infection.2 In contrast, the transmission rate is around 1%
during recurrent CMV infections.2 Recurrent CMV infec-
tions are common in pregnancy and constitute the major-
ity of congenital infections in populations with high
CMV-IgG seroprevalence.9 10
The CMV-IgG seroprevalence among women in repro-
ductive age ranges from 30% to 100% in different popula-
tions.9 11–23 Elements inﬂuencing CMV-IgG variability are
geography, socioeconomic status (SES) and the woman’s
age and parity.12 13 15 21 22 The highest CMV-IgG sero-
prevalence in pregnant women of 70–100% has been
observed in Africa, Asia and South America.9 15–17
Pregnant women in industrialised countries in Western
Europe and North America have demonstrated lower
CMV-IgG seroprevalence levels of about 30–50%.11–15 21–23
Factors associated with CMV-IgG seropositivity in devel-
oped countries are non-White race and lower SES.21 22
The high CMV-IgG seroprevalence in developing coun-
tries is probably due to lower SES and poor hygienic condi-
tions. Countries like Spain, Japan and Germany has
experienced a decrease in CMV-IgG seropreva-
lence.17 18 23 24 This could be explained as an improve-
ment of SES in these countries. CMV is known to be
transmitted through breast milk and infected infants shed
virus in the urine years after inoculation.25–27 Thus,
increased use of breastfeeding and day-care centre are sug-
gested reasons for higher CMV-IgG seroprevalence in
some developed countries, such as Sweden.28
Since socioeconomic factors may inﬂuence acquisition
patterns of viruses, updated studies are needed to
monitor the level of immunity in a population. Norway is
a highly developed country with a population of about
5 million people and 60 000 yearly deliveries. Two previ-
ous studies on CMV seroprevalence in pregnant
Norwegian women demonstrated CMV-IgG prevalences
of 69% (in 1992–1994)19 and 62.3% (in 2001),20 respect-
ively. However, both studies only addressed the overall
CMV-IgG seroprevalence19 20 and the study from 2001
was rather small (n=69).20 Thus, the aim of the present
study was to (1) examine the seroprevalence of CMV-IgG
and CMV-IgM antibodies in pregnant Norwegian women
and (2) investigate the inﬂuence of geography, age,
parity, education and income and (3) assess changes in
CMV seroprevalence over time.
METHODS
Study design and study population
This is a cross-sectional study including three study popu-
lations of pregnant Norwegian women. In study group 1,
The Norwegian Mother and Child Cohort Study (MoBa)
was included to assess CMV seroprevalence nationwide
and to investigate the inﬂuence of selected risk factors. In
study groups 2 and 3 two populations from Sør-Trøndelag
County collected at 14 years interval were included to
allow investigation of time trends.
Study group 1
The MoBa is a prospective population-based pregnancy
cohort study conducted by the Norwegian Institute of
Public Health.29 30 Participants were recruited from all
over Norway in 1999–2008 and 38.5% of invited women
consented to participate. The cohort now includes
108 000 children, 90 700 mothers and 71 500 fathers.
Blood samples were obtained from both parents during
pregnancy and from mothers and children (umbilical
cord) at birth. Follow-up is conducted by questionnaires
at regular intervals and by linkage to national health
registries. Several substudies are conducting additional
collections of data and biological materials.
For this study, a group of 1000 women were randomly
selected from the total of 46 127 pregnancies included
in the MoBa in 1999–2006. One of these women had
participated with two pregnancies and her second preg-
nancy was excluded. Forty-two women stated that their
ﬁrst language was not Norwegian and were excluded
from the overall analyses because of known ethnic var-
iances in CMV seroprevalence.13 15 Therefore, study
group 1 comprised a total number of 957 women and
plasma samples collected from women at the 17/18 ges-
tational week were used to examine levels of CMV-IgG
and CMV-IgM antibodies.
Study group 1 included all Norwegian counties and
was further divided into two large geographical regions;
North Norway (including Sør-Trøndelag County and all
counties further north) and South Norway (including
all counties south of Sør-Trøndelag County). The
women were divided into four age-deﬁned groups; <25,
25–30, 31–35 and >35 years of age. Parity was divided
into three groups; para 0, para 1 or para 2+.
Information about education and income level was
obtained from the MoBa questionnaires. Education was
divided into four different categories; Elementary
School, Secondary School, University Education <4 years
or University Education >4 years. Income was classiﬁed
into three groups of annual family income; low (<
€19 809/year for at least one parent), middle (€19 809–
€52 826/year for each parent) and high (>€52 826/year
for at least one parent).
The MoBa population has been used for several substu-
dies and linked to national health registries. The Medical
Birth Registry of Norway (MBRN) includes information
on all pregnant and delivering Norwegian women since
1968.31 Comparison of MoBa and MBRN registered preg-
nancies has shown more healthy pregnancies among
MoBa women than for the general population of preg-
nant Norwegian women.32 Thus, to compare the status of
study group 1 to all pregnant Norwegian women, MBRN
registered Norwegian women delivering in 1996–2006
(n=453 395) was used for comparison.
Study groups 2 and 3
To investigate changes in CMV seroprevalence over
time, serum samples collected in 1995 (study group 2)
and 2009 (study group 3) from pregnant women in
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Sør-Trøndelag County, a county in middle Norway, were
tested and compared. Sør-Trøndelag County has 290 000
inhabitants, with nearly 60% of the population living in
the city of Trondheim. In 2009, 3335 live born children
were born in Sør-Trøndelag County.31 Antenatal care
includes blood samples collected at ﬁrst health visit
between 8 and 12 weeks of pregnancy and blood
samples from all pregnant women in the county are sent
to the Department of Medical Microbiology at St. Olavs
Hospital, Trondheim University Hospital, for rubella
antibody analysis. Study group 2 include sera from preg-
nant women (n=1013) sent for rubella screening in
1995 and study group 3 include sera from pregnant
women (n=979) sent for rubella screening in 2009.
Thus, study groups 2 and 3 were randomly selected preg-
nant women from the same county with sera collected at
similar conditions and analysed in the same laboratory
for the presence of CMV-IgG and CMV-IgM antibodies.
In study group 3 information was available on female
age, and ages were divided into four age groups; <25,
25–30, 31–35 and >35 years of age.
CMV antibody testing
Plasma samples from study group 1 were stored at −80°C
and serum samples from study groups 2 and 3 were
stored at −20°C before testing. Antibody levels of
CMV-IgG and CMV-IgM in all samples were determined
by an ELISA (Medac, Hamburg, Germany). The sensitiv-
ity and speciﬁcity for the Medac CMV-IgG kit have been
estimated to 95.5–100% and 99.5%, respectively.33 The
Medac CMV-IgM kit has shown a very good speciﬁcity in
independent evaluations.34
Seropositivity was deﬁned according to the guidelines
given by the manufacturer. Sera yielding equivocal
values (for IgG; study group 1 (n=34) and study groups
2 and 3 (n=50) and for IgM; study group 1 (n=7) and
study groups 2 and 3 (n=10)), were excluded from
further analysis. Identical tests from the same manufac-
turer were used for analysing samples from all three
cohorts studied.
Statistical analysis
The primary outcome variable in this study was CMV
seropositivity, deﬁned as the presence of CMV-IgG or
CMV-IgM antibodies in serum or plasma. CMV sero-
prevalence is deﬁned as the prevalence of CMV sero-
positivity in a population.
All seroprevalence data were assessed as proportions
(per cent) with CIs of 95%. Univariate differences in
the proportions between groups were tested by χ2 test
and logistic regression test was used to calculate crude
and adjusted ORs of CMV seroprevalence by selected
predictors in bivariate and trivariate regression models.
The predictors were place of residence, age group,
parity, educational level, maternal income and family
income. Maternal age and education are both factors
known to inﬂuence CMV seroprevalence and were
adjusted for by logistic regression.
Two-sample t test was used to compare continuous
data between CMV seronegative and seropositive
mothers. Women with missing data were excluded from
the analysis. The level of statistical signiﬁcance was set to
p<0.05. All statistical analyses were performed using the
Predictive Analytics Software statistics V.18 (Chicago,
Illinois, USA).
RESULTS
Characteristics of the pregnant Norwegian women in study
group 1
Most women (88.8%) in study group 1 selected from the
MoBa reside in South Norway. Women of age groups
25–30 and 31–35 years were dominating in study group
1 (44.0% and 34.1%, respectively) and most women
were para 0 (42.6%) or para 1 (37.5%; table 1). The
level of education was fairly high (20.1% with >4 years
and 40.6% with <4 years of higher education) and most
women (48.7%) were in the middle family income
Table 1 Characteristics of study group 1 selected from
the Norwegian Mother and Child Cohort Study, 1999–2006
Study group 1
(n=957)
Proportions
(95% CI)
Place of residence*
North Norway 107 11.2 (9.3 to 13.4)
South Norway 848 88.8 (88.6 to 90.7)
Maternal age in years*
Overall mean
(SD) (%)
29.8 (4 to 5)
<25 118 12.4 (10.4 to 14.7)
25–30 420 44.0 (40.6 to 47.2)
31–35 326 34.1 (31.1 to 38.2)
>35 91 9.5 (7.6 to 11.4)
Parity (%)*
0 407 42.6 (39.6 to 45.8)
1 358 37.5 (34.6 to 40.5)
2+ 190 19.9 (17.4 to 22.2)
Educational level†
High school
(>4 years)
177 20.1 (17.5 to 22.9)
High school
(≤4 years)
358 40.6 (37.4 to 44.0)
Secondary
school
268 30.4 (27.4 to 33.6)
Elementary
school
78 8.9 (7.1 to 10.9)
Income‡
High 257 28.1 (25.5 to 31.2)
Middle 445 48.7 (45.5 to 52.0)
Low 211 23.1 (20.4 to 25.6)
*Missing values N=2.
†The education achieved by the women is given at separated
levels, where high education is referred to as University
Education, missing values on education N=77.
‡Income was classified into three groups of annual income; low
(<€19 809/year), middle (€19 809–€52 826/year) and high
(>€52 826/year), missing values for income N=44.
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category, while 28.1% of the women were in the high
family income category (table 1). Smoking prevalence
among the pregnant women in study group 1 was 12.7%
(data not shown).
The characteristics of study group 1 corresponded to
the MBRN registered general population of pregnant
Norwegian women regarding geography (81.7% gave
birth in South Norway and 18.3% in North Norway), age
and parity.31 However, study group 1 included fewer
smokers than the general population of pregnant
women (12.7% vs 15.7%). Additionally, fewer premature
babies (4.1% vs 7.2%), higher birth weight (3641 vs
3526 g), higher gestational age (39.5 vs 39.3 weeks) and
fewer children with low birth weight (1.8% vs 5.2%)
were observed in study group 1 selected from MoBa
than in the general population of pregnant Norwegian
women delivering between 1996 and 2006.
CMV antibodies among pregnant Norwegian women in
study group 1
In total, the seropositivity rate of CMV-IgM antibodies, indi-
cating a recent CMV infection, was 1.3% (95% CI 0.6% to
2.2%) (n=947), whereas the CMV-IgG seroprevalence was
59.9% (95% CI 56.7% to 63.1%; n=923) in study group
1. The inﬂuences of geography, age, parity, education and
income on CMV-IgG seroprevalence among the pregnant
Norwegian women of study group 1 are given in table 2.
Women from North Norway demonstrated a higher
CMV-IgG seroprevalence (72.1%) than those from South
Norway (58.5%; p<0.01; table 2).
No signiﬁcant difference in CMV-IgG seroprevalence
was observed with relation to woman’s age and parity,
although a tendency towards higher CMV-IgG seropreva-
lence (65.5%) was observed among the youngest women
(<25 years of age) compared with the elder groups
(table 2).
Women with the lowest educational level demonstrated
a higher CMV-IgG seroprevalence (70.5%) compared
with the highest education level (52.0%; p<0.01;
table 2). Different levels of education between women
from North Norway and South Norway were observed
(21.3% women reported >4 years of higher education in
South Norway compared to 10.4% women in North
Norway). The CMV-IgG seropositive data in North
Norway and South Norway were adjusted for education
and the OR for being CMV-IgG seropositive in North
Table 2 Cytomegalovirus (CMV)-IgG seropositivity according to selected risk factors in pregnant Norwegian women in study
group 1 from the Norwegian Mother and Child Cohort Study, 1999–2006
Study group
1 (n=923)†
CMV-IgG
seropositive n (%)
Crude OR‡
(95% CI)
Adjusted OR§
(95% CI)
Adjusted OR¶
(95% CI)
Place of residence††
South Norway 817 478 (58.5) 1.00 1.00 1.00
North Norway 104 75 (72.1) 1.83 (1.17 to 2.88)* 1.81 (1.15 to 2.84)* 1.56 (0.97 to 2.49)
Age group in years††
<25 116 76 (65.5) 1.00 1.00
25–30 404 231 (57.2) 0.70 (0.46 to 1.08) 0.78 (0.48 to 1.13)
31–35 314 193 (61.5) 0.84 (0.54 to 1.31) 0.98 (0.58 to 1.64)
>35 87 53 (60.9) 0.82 (0.46 to 1.46) 1.04 (0.56 to 1.96)
Parity††
0 391 230 (58.8) 1.00 1.00 1.00
1 343 202 (58.9) 1.00 (0.75 to 1.35) 1.02 (0.75 to 1.38) 0.94 (0.69 to 1.28)
>2 187 121 (64.7) 1.28 (0.89 to 1.84) 1.34 (0.91 to 1.96) 1.21 (0.83 to 1.77)
Education‡‡
High school (>4 years) 171 89 (52.0) 1.00 1.00
High school (≤4 years) 343 212 (61.8) 1.49 (1.03 to 2.16)** 1.56 (1.07 to 2.27)**
Secondary school 256 152 (59.4) 1.35 (0.91 to 1.99) 1.38 (0.91 to 2.09)
Elementary school 78 55 (70.5) 2.20 (1.24 to 3.90)* 2.21 (1.21 to 4.04)*
Income§§
High 247 133 (53.8) 1.00 1.00 1.00
Middle 427 260 (60.9) 1.33 (0.97 to 1.83) 1.40 (1.01 to 1.94)** 1.31 (0.95 to 1.82)
Low 205 129 (62.9) 1.46 (1.00 to 2.12) 1.51 (1.00 to 2.28)** 1.32 (0.87 to 2.02)
*p<0.01.
**p<0.05.
†Equivocal results N=34 were excluded.
‡OR for CMV seropositivity was calculated by logistic regression in successive bivariate (crude OR) and trivariate (adjusted OR) models.
§Adjusted for age N=921.
¶Adjusted for education N=846.
††Missing values N=2.
‡‡The education achieved by the women is given at separated levels, where high education is referred to as University education, missing
values on education N=77.
‡‡Income was classified into three groups of annual income; low (<€19 809/year), middle (€19 809–€52 826/year) and high (>€52 826/year),
missing values for income N=44.
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Norway compared to South Norway was reduced to 1.56
(95% CI 0.97 to 2.49). Even though the adjusted OR
was not signiﬁcant, geography still remained a strong
predictive factor for CMV-IgG seropositivity. A negative
and statistically signiﬁcant linear trend was observed
between CMV-IgG seroprevalence and family income
(linear χ2=4.03, p<0.05). Low income was associated with
close to 50% higher CMV-IgG seropositivity (compared
to the high family income).
CMV antibodies among pregnant women from
Sør-Trøndelag County in study groups 2 and 3
Comparing the pregnant women from Sør-Trøndelag
County collected in 1995 (study group 2) and 2009
(study group 3), revealed interesting differences in
CMV-IgG seroprevalence. The CMV-IgG seroprevalence
in 1995 was 63.1% (95% CI 60.0% to 66.1%), while in
2009, the CMV-IgG seroprevalence showed a marked
increase to 71.4% (95% CI 68.3% to 74.3%; p<0.01).
Similar changes were not observed for CMV-IgM (1995:
1.3%, 95% CI 0.69% to 2.18% and 2009: 1.7%, 95% CI
0.95% to 2.67%).
The age of the study group 2 women was not available,
but the mean age of the 3544 women delivering in
Sør-Trøndelag in 1995 was 28.0 (SD=4.9 years).31 The
mean age of the study group 3 women from 2009 was
29.1 years (SD=5.2 years) and the mean age for all the
3780 women giving birth in Sør-Trøndelag in 2009 was
29.6 (SD=5.2).31 The CMV-IgG seroprevalence related to
the women’s age groups in study group 3 is presented in
table 3. Generally, CMV-IgG seropositive (26.9 years,
SD=4.7 years) and seronegative (29.1 years, SD=5.2 years)
groups demonstrated no signiﬁcant age difference
(p=0.14). However, the youngest women (<25 years of
age) in study group 3 demonstrated the highest CMV-IgG
seropositivity (79%), as compared to women above
25 years of age (69.5% seropositivity; p<0.01).
DISCUSSION
This study shows an overall seroprevalence of 59.9% for
CMV-IgG and 1.3% for CMV-IgM among pregnant
Norwegian women (study group 1). The strongest risk
factors for CMV-IgG seropositivity were place of resi-
dence (highest CMV-IgG seropositivity in North Norway
(72.1%)) and low education (70.5%). More women with
higher education were living in South Norway than
North Norway and this could explain some of the geo-
graphical differences observed. The comparison of two
random samples of pregnant women in Sør-Trøndelag
County (study groups 2 and 3) suggested a CMV-IgG
seroprevalence increase over time, from 63.1% in 1995
to 71.4% in 2009. Interestingly, the highest CMV-IgG
seropositivity rate (79%) was detected in young women
(<25 years).
The strength of this study is the national population-
based design of study group 1 and the opportunity to
assess regional differences in CMV-IgG seroprevalence.
A limitation to this study is that the MoBa may be dis-
posed to some self-selection. Nilsen et al32 reported that
the women in the MoBa had experienced somewhat
healthier pregnancies as compared with the general
pregnant population in Norway, and this is also reﬂected
in our study group 1 from the MoBa. However, birth
weight and prematurity, which were different between
MoBa and MBRN in this material, have not been asso-
ciated with CMV-IgG seropositivity and should therefore
not have inﬂuenced the results.19 35 A higher level of
education was also observed in our study group from the
MoBa than generally in Norwegian women of the same
age groups.36 Since high SES is negatively correlated
with CMV-IgG seropositivity,13 15 21 22 such skewed selec-
tion of women in the MoBa may potentially lead to an
underestimation of CMV-IgG seroprevalence. However,
when women from Sør-Trøndelag County included in
the MoBa (n=19; study group 1) were compared with
the Sør-Trøndelag random sample from 2009 (study
group 3), fairly similar CMV-IgG seroprevalences were
observed (73.7% in the MoBa and 71.4% in the
Sør-Trøndelag random sample). It is therefore likely that
the estimates from the MoBa population represent the
true CMV-IgG seroprevalence in the pregnant
Norwegian population. Missing data among some
women in study group 1 could potentially bias the
results of the multivariate logistic regression analyses.
These women, however, have a higher CMV-IgG sero-
prevalence and are most likely lesser educated, hence
the associations presented are underestimates rather
than overestimates.
Although the Sør-Trøndelag groups (study groups 2
and 3) represent two unselected groups of pregnant
women, we cannot exclude the possibility that the
increasing immigration of non-ethnic Norwegians (from
2.5% in 1996 to 5.5% in 2009)37 could explain some of
the increase in CMV-IgG seroprevalence. However, a 3%
increase in non-ethnic Norwegians would lead to only
about a 1% increase in CMV-IgG seroprevalence, leaving
a change in the ethnic composition an unlikely explan-
ation for the increasing trend in CMV-IgG seropreva-
lence over time. The youngest women <25 years had the
Table 3 Cytomegalovirus (CMV)-IgG seropositivity
according to maternal age in study group 3, pregnant
women in Sør-Trøndelag County, 2009
Study
group 3
(n=929)†
CMV-IgG
seropositive
n (%)
Crude
OR (95% CI)
Age group in years
<25 176 139 (79.0) 1.00
5–30 394 268 (68.0) 0.57 (0.37 to 0.86)*
31–35 251 182 (72.5) 0.70 (0.46 to 1.11)
>35 108 74 (68.5) 0.60 (0.34 to 1.00)**
*p<0.01.
**p<0.05.
†Equivocal results N=50 were excluded.
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highest CMV-IgG seroprevalence and the increasing
trend in CMV-IgG seroprevalence could possibly be due
to an increased proportion of young pregnant women in
the population. However, in line with an increasing
mean age of delivering women in Norway (1995:
28.3 years, 2009: 29.7 years), the proportion of delivering
women <25 years of age in Sør-Trøndelag County was
24.6% in 1995 and only 16.7% in 2009.31
Sør-Trøndelag County, located in the middle of
Norway, represents a typical Norwegian region. This
study showed a statistically signiﬁcant increase in
CMV-IgG seroprevalence among pregnant women from
1995 to 2009 (study groups 2 and 3). Additionally, the
group from Sør-Trøndelag County in 2009 demonstrated
a particularly high CMV-IgG seroprevalence among the
youngest pregnant women. This is in contrast to other
studies, reporting an increased CMV-IgG seroprevalence
with increased age.12 15 18 Our ﬁndings suggest that
more Norwegian women are CMV infected as children
and teenagers now than before and indicate that the
CMV-IgG seroprevalence among pregnant Norwegian
women may be further increasing. This hypothesis is
supported by ﬁndings in the MoBa, where the youngest
pregnant women also demonstrated the highest
CMV-IgG seroprevalence, suggesting that the increase in
CMV-IgG seroprevalence may be occurring at a national
level.
Despite high socioeconomic conditions in the
Scandinavian countries, the CMV-IgG seroprevalence
seem to be relatively high. Including our estimates,
CMV-IgG seroprevalence in Norway and Sweden ranges
between 60% and 73%,19 20 38 whereas in other highly
developed countries such as the Netherlands, Ireland,
Canada and France, the CMV-IgG seroprevalence
numbers are reported as low as 30–50% among preg-
nant Caucasian women.11–15 As a country becomes more
developed, hygiene and socioeconomic conditions
improves and thus the CMV-IgG seroprevalence is
expected to decrease as reported in Spain, Japan and
Germany.17 18 23 24 The surprisingly high CMV-IgG sero-
prevalence levels in Norway may probably be ascribed to
high incidence of breastfeeding and children attending
group day-care facilities. Breast milk from CMV-IgG sero-
positive women contains detectable CMV-DNA and
infectious virus39 which can be transmitted to the
newborn baby.26 Group day-care is also well known to
increase the frequency of CMV infections in child-
hood.27 40 Both customs have increased in Norway since
the 1970s.41–44 Today, about 98% of Norwegian children
are breastfed during the ﬁrst week of life, while 89.7% of
all children attend day-care centre.43 45 Accordingly,
these changes may have inﬂuenced the increase in
CMV-IgG seroprevalence observed among young preg-
nant women of Sør-Trøndelag County in this study. A
relation between high breastfeeding rates and the use of
day-care centre in developed countries has previously
been suggested as a reason for high CMV-IgG seropreva-
lence rates,28 but updated Norwegian studies supporting
this have been missing. This study provides contemporary
data on an increase in CMV-IgG seroprevalence among
pregnant Norwegian women supporting this hypothesis.
There are also regional differences in breastfeeding and
the use of day-care centre in Norway, but these are too small
to explain the differences in CMV-IgG seroprevalence.46
This study demonstrates that CMV-IgG seroprevalence
in pregnant Norwegian women is relatively high, espe-
cially for a developed country. The frequency is highest
in the northern region and associated with fewer years
of education. The observed CMV-IgG seroprevalence
increase observed during the last 14 years, especially
among the youngest women, may be due to increased
breastfeeding rates of long duration and regular use of
day care center in the Norwegian society.
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